PROMESA: Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-Approach – evaluation of serious adverse events
Objective: In the PROMESA trial (ClinicalTrials Identifier: NCT02008721) Epigallocatechingallate (EGCG) a catechine that prevents pathological protein aggregation in vitro and can be purified from green…Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy
Objective: To assess the therapeutic efficacy of the caspase-1 inhibitor prodrug VX-765 on alpha-synuclein (α-syn) pathology and neuroprotection in a transgenic mouse model of multiple…Glucagon-like peptide 1 analogues for treating multiple system atrophy: A translational study
Objective: (i) To determine whether insulin resistance is a neuropathological feature of multiple system atrophy (MSA) and, (ii), to evaluate the therapeutic efficacy of the…Deep brain stimulation may lead to dramatic worsening of slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature
Objective: The aim of the present study is to describe one of the largest series of histologically proven multiple system atrophy (MSA) patients, who underwent…Systematic literature review of droxidopa in clinical trials for neurogenic orthostatic hypotension (nOH) in parkinsonism
Objective: The aim of this study was to review the published evidence for the efficacy, safety, and dosing practices of droxidopa treatment for symptomatic neurogenic…
- « Previous Page
- 1
- …
- 5
- 6
- 7